Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IBI133 |
| Synonyms | |
| Therapy Description |
IBI133 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting ERBB3 (HER3) linked to a DNA topoisomerase I inhibitor, which may induce apoptosis and inhibit proliferation of ERBB3 (HER3)-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IBI133 | IBI-133|IBI 133 | IBI133 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting ERBB3 (HER3) linked to a DNA topoisomerase I inhibitor, which may induce apoptosis and inhibit proliferation of ERBB3 (HER3)-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06170190 | Phase Ib/II | IBI133 | A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours | Completed | AUS | 0 |